ProMIS Neurosciences Inc. (NASDAQ: PMN) witnessed a significant surge in its share value on Monday, following a compelling presentation of preclinical data at AAIC 2023. The data showcased the promising therapeutic potential of their leading candidate, PMN310, for Alzheimer’s disease (AD), along with groundbreaking research on a computationally-derived AD vaccine.
The findings revealed that PMN310 exhibits superior selectivity in targeting toxic amyloid-beta oligomers compared to antibodies developed using synthetic oligomers. This breakthrough discovery highlights the immense possibilities in improving patient outcomes and positively impacting their families’ lives.
Gail Farfel, the CEO of ProMIS Neurosciences, expressed enthusiasm about the new data presented at the AAIC conference, emphasizing the importance of understanding Alzheimer’s disease mechanisms and advancing treatment options. The growing recognition of the benefits associated with targeting Aβ oligomers underscores the potential advantage of ProMIS’ PMN310 antibody and AβO vaccine candidates.
Moreover, in a significant development, ProMIS received FDA clearance in May 2023 for its Investigational New Drug (IND) application for PMN310, paving the way for potential AD treatment.
The remarkable progress made by ProMIS Neurosciences offers a ray of hope for individuals affected by Alzheimer’s disease, signaling a potential breakthrough in the quest for effective therapies.